InspireMD, Inc. (NYSEAMERICAN:NSPR – Get Rating)'s stock price fell 1.6% on Monday . The company traded as low as $1.79 and last traded at $1.80. 5,429 shares changed hands during trading, a decline of 77% from the average session volume of 23,743 shares. The stock had previously closed at $1.83.
InspireMD Stock Performance
The company has a market capitalization of $14.98 million, a price-to-earnings ratio of -0.60 and a beta of 1.51.
Get
InspireMD alerts:
InspireMD (NYSEAMERICAN:NSPR – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The medical equipment provider reported ($0.59) earnings per share for the quarter. InspireMD had a negative return on equity of 43.80% and a negative net margin of 448.33%. The company had revenue of $1.53 million for the quarter.
Insider Activity at InspireMD
In other InspireMD news, Director Gary S. Roubin acquired 35,500 shares of the stock in a transaction that occurred on Thursday, August 18th. The shares were purchased at an average cost of $1.91 per share, with a total value of $67,805.00. Following the purchase, the director now owns 164,194 shares in the company, valued at $313,610.54. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.80% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On InspireMD
A hedge fund recently bought a new stake in InspireMD stock. Millennium Management LLC purchased a new stake in InspireMD, Inc. (NYSEAMERICAN:NSPR – Get Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,191 shares of the medical equipment provider's stock, valued at approximately $28,000. Millennium Management LLC owned 0.17% of InspireMD as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 2.09% of the company's stock.
About InspireMD
(Get Rating)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.
Read More
- Get a free copy of the StockNews.com research report on InspireMD (NSPR)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
